261 related articles for article (PubMed ID: 28838386)
21. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Tong JH; Yeung SF; Chan AW; Chung LY; Chau SL; Lung RW; Tong CY; Chow C; Tin EK; Yu YH; Li H; Pan Y; Chak WP; Ng CS; Mok TS; To KF
Clin Cancer Res; 2016 Jun; 22(12):3048-56. PubMed ID: 26847053
[TBL] [Abstract][Full Text] [Related]
22. Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer.
Wynes MW; Konopa K; Singh S; Reyna-Asuncion B; Ranger-Moore J; Sternau A; Christoph DC; Dziadziuszko R; Jassem J; Hirsch FR
J Thorac Oncol; 2012 Jun; 7(6):982-92. PubMed ID: 22551903
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures.
Guo B; Cen H; Tan X; Liu W; Ke Q
PLoS One; 2014; 9(6):e99399. PubMed ID: 24922520
[TBL] [Abstract][Full Text] [Related]
24. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
[TBL] [Abstract][Full Text] [Related]
25. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
26. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.
Peters S; Letovanec I; Mauer M; Dafni U; Ejedepang D; Biernat W; Bubendorf L; Warth A; Pokharel S; Reinmuth N; Majem Tarruella M; Casas-Martin J; Tsourti Z; Marti N; Kammler R; Danson S; O'Brien M; Stahel RA
Lung Cancer; 2023 Jan; 175():141-151. PubMed ID: 36535121
[TBL] [Abstract][Full Text] [Related]
27. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer.
Wulf MA; Bode B; Zimmermann D; Rufibach K; Weder W; Moch H; Soltermann A; Tischler V
Am J Surg Pathol; 2012 Dec; 36(12):1801-8. PubMed ID: 23154768
[TBL] [Abstract][Full Text] [Related]
28. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma.
Wagner PL; Stiedl AC; Wilbertz T; Petersen K; Scheble V; Menon R; Reischl M; Mikut R; Rubin MA; Fend F; Moch H; Soltermann A; Weder W; Altorki NK; Perner S
Lung Cancer; 2011 Oct; 74(1):118-23. PubMed ID: 21477882
[TBL] [Abstract][Full Text] [Related]
29. High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.
Feng Y; Minca EC; Lanigan C; Liu A; Zhang W; Yin L; Pennell NA; Farver C; Tubbs R; Ma PC
J Thorac Oncol; 2014 May; 9(5):646-53. PubMed ID: 24722154
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification.
Ding C; Qiu Y; Zhang J; Wei W; Gao H; Yuan Y; Wang X
BMC Pulm Med; 2023 Jul; 23(1):240. PubMed ID: 37400762
[TBL] [Abstract][Full Text] [Related]
31. Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.
Kron A; Scheffler M; Heydt C; Ruge L; Schaepers C; Eisert AK; Merkelbach-Bruse S; Riedel R; Nogova L; Fischer RN; Michels S; Abdulla DSY; Koleczko S; Fassunke J; Schultheis AM; Kron F; Ueckeroth F; Wessling G; Sueptitz J; Beckers F; Braess J; Panse J; Grohé C; Hamm M; Kabitz HJ; Kambartel K; Kaminsky B; Krueger S; Schulte C; Lorenz J; Lorenzen J; Meister W; Meyer A; Kappes J; Reinmuth N; Schaaf B; Schulte W; Serke M; Buettner R; Wolf J
J Thorac Oncol; 2021 Apr; 16(4):572-582. PubMed ID: 33309988
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
Blackhall FH; Peters S; Bubendorf L; Dafni U; Kerr KM; Hager H; Soltermann A; O'Byrne KJ; Dooms C; Sejda A; Hernández-Losa J; Marchetti A; Savic S; Tan Q; Thunnissen E; Speel EJ; Cheney R; Nonaka D; de Jong J; Martorell M; Letovanec I; Rosell R; Stahel RA
J Clin Oncol; 2014 Sep; 32(25):2780-7. PubMed ID: 25071109
[TBL] [Abstract][Full Text] [Related]
33. Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients.
Ludovini V; Flacco A; Bianconi F; Ragusa M; Vannucci J; Bellezza G; Chiari R; Minotti V; Pistola L; Tofanetti FR; Siggillino A; Baldelli E; Sidoni A; Daddi N; Puma F; Varella-Garcia M; Crinò L
Cancer Chemother Pharmacol; 2013 Mar; 71(3):671-80. PubMed ID: 23314677
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
Chen YT; Chang JW; Liu HP; Yu TF; Chiu YT; Hsieh JJ; Chen YT; Chen YR; Wu HD; Huang SF
J Thorac Oncol; 2011 Dec; 6(12):2027-35. PubMed ID: 22052229
[TBL] [Abstract][Full Text] [Related]
35. MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC.
Sterlacci W; Fiegl M; Gugger M; Bubendorf L; Savic S; Tzankov A
Virchows Arch; 2017 Jul; 471(1):49-55. PubMed ID: 28528511
[TBL] [Abstract][Full Text] [Related]
36. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
Zheng D; Wang R; Ye T; Yu S; Hu H; Shen X; Li Y; Ji H; Sun Y; Chen H
Oncotarget; 2016 Jul; 7(27):41691-41702. PubMed ID: 27223439
[TBL] [Abstract][Full Text] [Related]
37. p95HER2 truncated form in resected non-small cell lung cancer.
Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M
J Thorac Oncol; 2012 Mar; 7(3):520-7. PubMed ID: 22307009
[TBL] [Abstract][Full Text] [Related]
38. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
39. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
[TBL] [Abstract][Full Text] [Related]
40. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]